GRANTS & Funding - Linc Grant Scheme 2022
TRI, Metro South Health and Mater Research have joined together to offer the annual LINC grants, worth up to $50,000 each. These grants are aimed at fostering new collaborative research projects between TRI-based researchers and Mater or Metro South Health clinicians. FIND OUT MORE
Requesting a Letter of support from TRI for Funding
If you are interested in applying for funding support from TRI please contact [email protected] for a link to the application form. Applications need to be made three weeks prior to the submission deadline for the relevant grant applications, and must include:
- What is novel about the proposal and what is its value-add as a TRI investment for the TRI community.
- Previous funding requests to TRI (successful or not) to the same or a different funding body.
- How the application meets each of the criteria against which it will be assessed by TRI.
- Support from the Institute Director at TRI of the primary applicant (CIA).
Read the full eligibility criteria and terms and conditions here
past FUNDING PROGRAMS AT TRI
Between 2015 and 2019. TRI ran the Spore and Drive grant schemes for translational research projects based at the institute. The aim was to support researchers progress their discoveries and translate their findings into the clinic. During the time the schemes run, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745.
|
Year awarded |
Grant scheme |
Principal Investigator |
Project title |
|
2015 |
Spore |
Dr Michelle Hill |
Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools |
|
2015 |
Spore |
Dr Antje Blumenthal |
Towards biomarkers for patient stratification in sepsis |
|
2015 |
Spore |
Prof Rik Thompson |
Portable, single-sided MRI for routine, low-cost analysis of mammographic density |
|
2015 |
Spore |
Prof Ken O'Byrne |
Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability |
|
2016 |
Spore |
A/Prof Jyotsna Batra |
Novel MicroRNA’s as potential targets for treating prostate cancer |
|
2016 |
Spore |
A/Prof Chamindie Punyadeera |
Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy |
|
2018 |
Spore |
Prof Gerald Holtmann |
Modulation of the GI Microbiome with probiotics to treat constipation |
|
2018 |
Spore |
Prof John Hooper |
Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer |
|
2018 |
Spore |
Dr Arutha Kulasinghe |
Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer? |
|
2018 |
Spore |
Prof Peter Soyer |
Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies |
|
2019 |
Spore |
A/Prof Jyotsna Batra |
Improving the PSA test to detect all lethal prostate cancers |
|
2019 |
Spore |
Prof Ben Panizza |
Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC) |
|
2019 |
Drive |
Prof Sandro Porceddu |
Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer |
